Fludarabine
Cellular Phase Chronic Idiopathic Myelofibrosis
Explore 3 assets in Cellular Phase Chronic Idiopathic Myelofibrosis →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02528877CT.gov Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cellular Phase Chronic Idiopathic Myelofibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | City of Hope Medical Center | P1 | CC · 43 |
| Azacitidine | M.D. Anderson Cancer Center | P1/2 | CCC |
| Pevonedistat | M.D. Anderson Cancer Center | P1/2 | CCC |
| Venetoclax | M.D. Anderson Cancer Center | P1/2 | CCC |
| Ruxolitinib Phosphate | City of Hope Medical Center | P1 | CC |
| Tacrolimus | City of Hope Medical Center | P1 | CC |
| Sirolimus | City of Hope Medical Center | P1 | CC |
| Melphalan | City of Hope Medical Center | P1 | CC |
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Cellular Phase Chronic Idiopathic Myelofibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-cellular-phase-chronic-idiopathic-myelofibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →